证券代码：002826 股票简称：易明医药 公告编号：2023-051 西藏易明西雅医药科技股份有限公司 关于召开 2023 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 西藏易明西雅医药科技股份有限公司（以下简称"本公司"或"公司"）第三届 董事会第十三次会议审议通过了《关于召开 2023 年第二次临时股东大会的议案》， 定于 2023 年 9 月 7 日（星期四）下午 14:00 召开 2023 年第二次临时股东大会， 现将本次会议的相关事项通知如下： 一、本次会议召开的基本情况 1、会议届次：2023 年第二次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：公司第三届董事会第十三次会议审议通过相 关议案，本次股东大会会议的召开符合有关法律、行政法规、部门规章、规范性 文件和《公司章程》等的规定。 4、会议表决方式：现场记名书面投票与网络投票相结合 5、会议时间： （1）现场会议时间为：2023 年 9 月 7 日（星期四）下午 14:00。 同一股东只能采取现场、网络表决方式的一种。如同一股东通过现场、 ...

证券代码：002826 证券简称：易明医药 公告编号：2023-047 西藏易明西雅医药科技股份有限公司 第三届董事会第十三次会议决议公告 董事和高级管理人员在全面了解和审核公司 2023 年半年度报告及其摘要后 一致认为：公司 2023 年半年度报告的编制和审核程序符合法律、行政法规和中 国证监会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在 任何虚假记载、误导性陈述或者重大遗漏。 《公司 2023 年半年度报告》刊登在巨潮资讯网（http://www.cninfo.com.cn） 供投资者查阅，《公司 2023 年半年度报告摘要》同时刊登在《证券日报》、《证 券时报》、巨潮资讯网（http://www.cninfo.com.cn）供投资者查阅。 1 2、审议通过了《关于增加经营范围并修订<公司章程>的议案》 一、董事会会议召开情况 西藏易明西雅医药科技股份有限公司（以下简称"公司"及"本公司"）第 三届董事会已于 2023 年 8 月 10 日以电子邮件方式通知了全体董事，本次会议于 2023 年 8 月 21 日在公司会议室以现场与通讯相结合的方式召开。 本次会议应到董事 7 人，实到董 ...

证券代码：002826 证券简称：易明医药 公告编号：2023-046 西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"）于 2023年8月14日收到西藏拉萨经济技术开发区管理委员会拨付的2022年度产业扶 持专项资金27,914,871.00元，占最近一期经审计净利润比例为63.25%。本公司 根据拉萨经开区经济发展局下发的《关于2022年产业扶持专项资金政策执行情况 的说明》于2022年度已确认其他收益16,000,000.00元，差额部分11,914,871.00 元将于实际收到款项的当月计入2023年其他收益。 二、补助的类型及其对公司的影响 1、补助的类型 根据《企业会计准则第16号-政府补助》的规定，与资产相关的政府补助， 是指企业取得的、用于购建或以其他方式形成长期资产的政府补助；与收益相关 的政府补助，是指除与资产相关的政府补助之外的政府补助。 西藏易明西雅医药科技股份有限公司 关于获得政府补助的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、获取补助的基本情况 公司本次获得的政府补助属于与收益相关的政府补助。 4、风险 ...

证券代码： 002826 证券简称：易明医药 西藏易明西雅医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------|---------------|--------------|----------| | | | | 2023-001 | | | □特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 √ | 业绩说明会 | | | 投资者关系活动 | □ 新闻发布会 | □ 路演活动 | | | 类别 | □ 现场参观 | | | □ 其他 （请文字说明其他活动内容） 参与单位名称及 通过"全景·路演天下"（http://rs.p5w.net）参与本次 2022 年度网 人员姓名 上业绩说明会的投资者 时间 2023 年 5 月 9 日 (星期二) 下午 15:00~17:00 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待人 1、董事长、总经理许可 员姓名 2、董事、财务总监周敏 3、独立董事肖兴刚 4、副总经理、董事会秘书李前进 形式 网 ...

证券代码：002826 证券简称：易明医药 公告编号：2023-033 西藏易明西雅医药科技股份有限公司 关于举办 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2 出席本次网上业绩说明会的人员有：公司董事长、总经理许可先生；财务总 监周敏女士；独立董事肖兴刚先生；董事会秘书、副总经理李前进女士。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年5月8 日（星期一）12:00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集 专题页面进行提问。公司将在2022年度业绩说明会上，对投资者普遍关注的问题 进行回答。欢迎广大投资者积极参与！ （问题征集专题页面二维码） 特此公告。 1 西藏易明西雅医药科技股份有限公司 董事会 二〇二三年五月五日 西藏易明西雅医药科技股份有限公司（以下称"公司"）已于2023年4月27日 在巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022年年度报告 ...

Financial Performance - The company's operating revenue for 2022 was CNY 856,734,308, representing an increase of 18.10% compared to CNY 725,459,075 in 2021[19] - The net profit attributable to shareholders for 2022 was CNY 44,135,409, a 3.91% increase from CNY 42,476,491 in 2021[19] - The net profit after deducting non-recurring gains and losses was CNY 39,487,468, up 2.21% from CNY 38,634,658 in 2021[19] - The total assets at the end of 2022 were CNY 1,018,204,646, reflecting a 23.50% increase from CNY 824,473,281 at the end of 2021[19] - The net assets attributable to shareholders increased by 3.89% to CNY 745,293,911 at the end of 2022 from CNY 717,389,579 at the end of 2021[19] - The basic earnings per share for 2022 were CNY 0.23, a 4.55% increase from CNY 0.22 in 2021[19] - The company achieved a revenue of 856.73 million yuan in 2022, representing an 18.10% increase year-over-year[49] - Net profit attributable to shareholders was 44.14 million yuan, reflecting a 3.91% growth compared to the previous year[49] - The company reported a total revenue of 1.5 billion yuan for the fiscal year 2022, representing a year-over-year increase of 15%[134] - The net profit for the year was 300 million yuan, which is a 20% increase compared to the previous year[134] Cash Flow and Investments - The net cash flow from operating activities decreased by 37.50% to CNY 68,453,222 from CNY 109,522,210 in 2021[19] - The company received government subsidies totaling CNY 3,928,995.50 in 2022, which are closely related to its normal business operations[24] - The company reported a financial expense reduction of 41.71%, resulting in a financial income of -¥1,569,331.57 for 2022[70] - Investment cash inflow decreased by 16.38% to ¥201,482,652.27, while net cash flow from investment activities improved by 96.80% to -¥1,715,400.76[76] - Financing cash inflow reached ¥50,000,000.00, with net cash flow from financing activities increasing by 146.61% to ¥27,592,000.02[75] - The company reported a significant decrease in investment amounting to ¥3,198,053.03, down 87.31% from ¥25,195,329.17 in the previous year[85] Market and Product Development - The company is focusing on optimizing its operational costs in response to ongoing healthcare reforms and procurement policies, which pose challenges to its business model[32] - The company anticipates continued growth in the pharmaceutical sector driven by increasing healthcare awareness and government investments in medical services[30] - The company is actively involved in the development of traditional Chinese medicine, with recent policies promoting the high-quality development of this sector[35] - The company has established partnerships for the development of new drugs, such as the Guo Liao Pi Injection (Xintong®) and Sodium Nifedipine Injection (Yimeifen®), enhancing its product portfolio[40] - The company is focused on optimizing production processes and reducing costs to improve product quality and efficiency in response to market pressures[34] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[134] - The company plans to enhance production capacity by building new production lines and improving production processes to support core product growth[95] - The company aims to strengthen partnerships with major pharmaceutical manufacturers and distributors to enhance its competitive position in the pharmaceutical distribution sector[95] Corporate Governance and Management - The company has established a complete internal audit system, ensuring the integrity and effectiveness of internal controls, with no fraud detected during the reporting period[107] - The financial department operates independently, with no shared bank accounts with controlling shareholders, and the company has a complete financial accounting system[112] - The company has a governance structure that includes a shareholders' meeting, board of directors, and supervisory board, all functioning independently[116] - The company has disclosed 52 announcements and 4 periodic reports, ensuring timely and accurate information for shareholders[106] - The company has a clear ownership structure, with all assets related to production and operations legally owned or controlled, ensuring no asset occupation by controlling shareholders[114] - The company has a history of significant management changes, indicating a dynamic approach to leadership and governance[122] - The company has appointed a new chairman and financial director, indicating a change in leadership and management structure[119] - The company is leveraging its experienced management team to drive growth and innovation in the pharmaceutical sector[124] Social Responsibility and Community Engagement - The company emphasizes corporate social responsibility, aiming to create maximum value for stakeholders while contributing to public health[98] - The company has actively communicated with stakeholders, aiming to balance interests and fulfill social responsibilities[108] - The company has implemented an employee stock ownership plan to enhance long-term motivation and share the company's growth with its employees[182] - The company has made significant contributions to local communities, including donations of agricultural production materials to assist impoverished households[184] - The company has maintained a strong commitment to corporate social responsibility, actively engaging in community support and poverty alleviation initiatives[184] - The company actively participated in poverty alleviation efforts, donating medicines and funds to assist impoverished communities in Tibet, including 100,000 yuan for housing repairs in Bai Rang Village[185] Environmental Compliance - The company has complied with environmental protection laws and standards, including the "Environmental Protection Law" and "Water Pollution Prevention Law" in 2022[170] - The company has obtained a national pollutant discharge permit, with the permit number 91510000620854656KP001, and submits quarterly and annual reports to the ecological environment bureau[170] - The company has been recognized as a "Good Environmental Protection Enterprise" by the Sichuan Provincial Department of Ecology and Environment during the reporting period[177] - The wastewater treatment system has a designed daily processing capacity of 450 tons, with an inflow COD concentration of approximately 3000 mg/L and an outflow COD concentration of around 45 mg/L, significantly below the standard of 300 mg/L[173] - The company invested a total of 1.2005 million yuan in environmental governance and protection in 2022, including an environmental protection tax payment of 640.93 yuan[177] Future Outlook and Strategic Goals - The company plans to distribute a cash dividend of CNY 1 per 10 shares, totaling CNY 19,067,775.00, based on a total share capital of 190,682,250 shares as of December 31, 2022[155] - The company has set a performance guidance of 10% revenue growth for the next fiscal year[134] - The company plans to adapt its sales model and enhance team personnel to promote performance recovery in 2023 as the economic environment gradually improves[193] - The company is focused on protecting investor interests and has outlined measures to address any potential losses incurred by investors[192] - The company projected net profits for the years 2021, 2022, 2023, and 2024 to be RMB 6 million, RMB 6.9 million, RMB 7.935 million, and RMB 9.12525 million respectively[195]

Financial Performance - The company's revenue for Q1 2023 was ¥171,430,742.25, a decrease of 8.05% compared to ¥186,434,809.99 in the same period last year[4] - Net profit attributable to shareholders was ¥8,363,504.12, down 1.93% from ¥8,528,415.37 year-on-year[4] - Total operating revenue for Q1 2023 was CNY 171,430,742.25, a decrease of 8.5% compared to CNY 186,434,809.99 in Q1 2022[28] - Net profit for Q1 2023 was CNY 8,478,872.65, slightly down by 1.9% from CNY 8,639,617.30 in Q1 2022[30] - The total comprehensive income for Q1 2023 was CNY 8,391,700.71, compared to CNY 8,637,294.56 in Q1 2022, indicating a decrease of 2.8%[30] Cash Flow - The net cash flow from operating activities increased significantly to ¥31,828,337.43, a 713.24% improvement from -¥5,190,203.15 in Q1 2022[10] - Cash inflow from operating activities increased to CNY 224,475,914.77 in Q1 2023, compared to CNY 211,295,382.30 in Q1 2022, reflecting a growth of 6.2%[32] - The net cash flow from investing activities was -¥100,219,757.00, which is a decline of ¥51,446,057.00 year-over-year[34] - The net cash flow from financing activities was -¥462,499.99, indicating no cash inflow from financing activities[34] - The net increase in cash and cash equivalents was -¥68,936,595.76, compared to a decrease of ¥56,638,556.05 in the previous period[35] - The ending balance of cash and cash equivalents was ¥207,346,181.35, down from ¥276,282,777.11 at the beginning of the period[35] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥1,015,182,951.21, a slight decrease of 0.30% from ¥1,018,204,645.88 at the end of the previous year[5] - The company's total liabilities decreased to CNY 256,795,042.24 in Q1 2023 from CNY 268,208,437.62 in Q1 2022, a reduction of 4.3%[26] - The total current assets as of March 31, 2023, amount to ¥578,091,376.85, slightly up from ¥575,009,326.03 at the beginning of the year[23] - The total assets of the company are ¥1,015,182,951.21, down from ¥1,018,204,645.88 at the beginning of the year[24] - The accounts receivable decreased from ¥162,609,114.23 to ¥129,932,347.05 during the reporting period[23] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,848[12] - The largest shareholder, Gao Fan, holds 25.59% of shares, amounting to 48,800,382 shares, with 17,120,000 shares pledged[12] Investments and Expenses - Research and development expenses decreased by 51.49% to ¥498,451.91 from ¥1,027,543.70 in the same period last year[9] - The company reported a significant increase in credit impairment losses, which rose by 334.06% to ¥1,755,052.14 compared to a decrease of ¥749,839.71 in Q1 2022[9] - The company received government subsidies amounting to ¥582,278.88, which are closely related to its normal business operations[6] - The company has increased its short-term financial investments, with trading financial assets reaching ¥100,000,000.00, marking a 100% increase[9] - The company plans to invest $6,000,000 to acquire a 21.43% stake in Pier 88 Health Limited through its wholly-owned subsidiary TAPI Healthcare Inc.[15] Audit Information - The company did not undergo an audit for the first quarter report[36]

证券代码：002826 证券简称：易明医药 编号：2019-001 西藏易明西雅医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------|--------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | £ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | R 现场参观 | | | | □ 其他 | | | 参与单位名称及 人员姓名 | 银河证券、中投证券、东方财富等 | 27 名机构及个人投资者参会 | | 时间 | 2019 年 8 月 13 | 日 15:30-18:00 | | 地点 | 拉萨经济技术开发区林琼岗路 | 6 号西藏易明西雅医药科技股份 | | | 有限公司 | | | 上市公司接待人 | 董事、副董事长：周战先生 | | | 员姓名 | 副总经理、董事会秘书：许可先生 | | 1 / 3 | --- | --- | ...

1 证券代码：002826 证券简称：易明医药 编号：2021-001 西藏易明西雅医药科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

Financial Performance - The company's revenue for Q3 2022 was ¥206,056,228.21, representing a 14.86% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥9,271,623.79, a 33.30% increase year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,074,465.58, up by 9.48% from the previous year[4] - The basic earnings per share for Q3 2022 was ¥0.05, a 25.00% increase compared to the same period last year[4] - Operating revenue for the first nine months of 2022 reached CNY 591.77 million, an increase of 14.21% compared to CNY 518.14 million in the same period of 2021[9] - Total operating revenue for Q3 2022 reached CNY 591,767,346.30, an increase of 14.2% compared to CNY 518,143,668.07 in Q3 2021[24] - Net profit for Q3 2022 was CNY 21,481,158.04, representing a 24.5% increase from CNY 17,172,369.51 in the same period last year[25] - Earnings per share (EPS) for Q3 2022 was CNY 0.11, compared to CNY 0.09 in Q3 2021, indicating a growth of 22.2%[26] Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥922,221,097.15, reflecting an 11.86% increase from the end of the previous year[4] - Total assets increased to CNY 922,221,097.15 from CNY 824,473,281.11, marking a rise of 11.8%[22] - Total liabilities rose to CNY 199,200,460.17, up from CNY 104,362,512.05, which is an increase of 90.8%[22] - The total equity attributable to shareholders at the end of Q3 2022 was ¥720,063,895.43, a slight increase of 0.37% from the previous year[4] - The total equity attributable to shareholders increased to CNY 720,063,895.43 from CNY 717,389,579.34, reflecting a slight growth of 0.4%[22] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥91,887,610.24, a 32.69% increase compared to the same period last year[4] - Net cash flow from operating activities increased by 32.69% to CNY 91.89 million, up from CNY 69.25 million year-on-year[10] - Operating cash flow for the current period was ¥91,887,610.24, an increase of 32.9% compared to ¥69,249,556.94 in the previous period[27] - Total cash inflow from operating activities was ¥721,398,791.01, down 25.3% from ¥965,164,381.49 in the previous period[27] - Cash outflow from operating activities totaled ¥629,511,180.77, a decrease of 29.7% compared to ¥895,914,824.55 in the previous period[27] - Cash received from investment recovery was ¥100,000,000.00, down from ¥210,000,000.00 in the previous period[29] - The ending cash and cash equivalents balance increased to ¥200,638,206.96 from ¥140,234,893.13 in the previous period[29] Accounts Management - The company reported a significant increase in accounts receivable, which rose by 140.92% to ¥88,232,258.49 compared to the end of 2021[8] - Accounts payable surged by 313.53% to CNY 64.81 million, up from CNY 15.67 million, driven by business growth and accrued promotional service fees[10] - Other receivables decreased by 64.63% to CNY 32.95 million, down from CNY 93.17 million, primarily due to changes in sales management and settlement methods[9] - Contract liabilities decreased by 84.44%, indicating a reduction in advance payments received compared to the previous year[10] Expenses and Investments - Research and development expenses decreased by 51.75% to CNY 3.34 million, down from CNY 6.93 million, due to the completion of a previous project[10] - The company reported a net cash outflow from investing activities of CNY 101.40 million, an increase of 83.67% compared to the previous year[10] - The company has committed to a total of ¥10,000,000 in wealth management products, all of which are backed by its own funds[16] - The company has invested in structured deposits with a reference annualized yield of 3.3%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,709[13] - The largest shareholder, Gao Fan, holds 26.40% of the shares, amounting to 50,335,682 shares, with 19,716,000 shares pledged[13] - The top ten shareholders do not have any disclosed relationships or agreements regarding concerted actions[13] Tax and Other Income - Income tax expenses increased by 47.22% to CNY 7.43 million, up from CNY 5.04 million, corresponding to profit growth[10] - Other comprehensive income increased by 148.53% to CNY 31.65 million, compared to a loss of CNY 65.23 million in the previous year[9] Audit Information - The company did not conduct an audit for the third quarter report[30]